Skip to main content

Skadden, Arps, Slate, Meagher & Flom and Zhong Lun Law Firm have advised China’s Everest Medicines on its $451 million IPO in Hong Kong, with Kirkland & Ellis and Tian Yuan Law Firm advising the joint sponsors and underwriters.

Everest Medicines, a China-based clinical-stage biopharmaceutical company created by C-Bridge Capital in July 2017, develops, licenses and commercialises potentially novel transformative therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets.

It is the second Chinese biopharmaceutical company to go public in Hong Kong this month, after JHBP (CY) Holdings.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Top international firms act on landmark $7.1 bln ESR take-private deal

by Nimitt Dixit |

Global law firms Freshfields, Latham & Watkins, Kirkland & Ellis, Paul, Weiss, Rifkind, Wharton & Garrison and Cleary Gottlieb Steen & Hamilton have steered an offer to take the Hong Kong-listed ESR Group private in a deal valued at $7.1 billion.

Deals

Fangda, KWM act on HKAA’s $592 mln acquisition of Zhuhai Airport stake

by Hu Yangxiaoxiao 胡阳潇潇 |

Fangda Partners has advised the Hong Kong Airport Authority (HKAA) on its agreement to purchase a 35 percent stake in Zhuhai Airport for approximately $592 million, with King & Wood Mallesons representing the seller, Zhuhai Transportation.

Deals

BKL, Yoon & Yang guide $640 mln Korean real estate deal

by Nimitt Dixit |

Top South Korean firms Bae, Kim & Lee and Yoon & Yang have advised the seller and buyer, respectively, in the acquisition of Donuimun D Tower in central Seoul by NH Nonghyup REITs Management for $640 million from Mastern Asset Management.